5MeODMT Benzoate Salt Formulation via Cyclodextrin Complexation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
5-methoxy-N,N-dimethyltryptamine (5MeODMT) is not well understood and poses challenges in formulating effective pharmaceutically useful compositions due to its handling difficulties and limited exploration of its uses.
Innovation Solution
Development of pharmaceutically acceptable salts, specifically benzoate salts of 5MeODMT, with adjustable dosage forms and delivery methods, including oral, transdermal, inhalable, and rectal forms, to enhance handling and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 5MeODMT is formulated for effective delivery, then therapeutic efficacy is improved, but handling difficulties and formulation challenges increase
Solution Approach 1:
The patent uses cyclodextrins as intermediary molecules that form inclusion complexes with 5MeODMT. The cyclodextrin cavity encapsulates the tryptamine molecule, creating a stable complex that is easier to handle and formulate while maintaining therapeutic efficacy. This mediator approach resolves the contradiction by making the difficult-to-handle 5MeODMT more manageable through molecular complexation.
Solution Approach 2:
The patent creates composite formulations combining 5MeODMT with excipients including mucoadhesive enhancers and cyclodextrins. These composite materials integrate multiple functional components that collectively improve handling properties, stability, and delivery efficiency while maintaining the active compound's therapeutic effects.
2Reliability
If particle size is reduced to enhance bioavailability, then absorption is improved, but manufacturing complexity increases
Solution Approach 1:
The patent systematically varies particle size parameters to optimize bioavailability. By controlling particle size within specific ranges and using different polymorphic forms, the formulation achieves enhanced absorption without requiring overly complex manufacturing processes. The parameter optimization approach balances performance improvement with manufacturing feasibility.
3Reliability
If permeation is increased for effective delivery, then bioavailability is improved, but mucosal irritation increases
Solution Approach 1:
The patent employs mucoadhesive enhancers as intermediary substances that facilitate drug permeation through mucosal barriers without directly causing irritation. These mediators enable controlled transport of 5MeODMT across mucosal membranes, improving bioavailability while the mucoadhesive properties provide a protective effect that reduces direct irritation to the mucosa.
Solution Approach 2:
The patent converts the potentially harmful high permeation capability into a beneficial effect by using controlled release mechanisms and mucoadhesive formulations. The high permeation property, which could cause irritation, is harnessed in a controlled manner to improve bioavailability while the formulation design mitigates the harmful irritation effects, effectively converting a potential harm into a benefit.
Data Source
Figure 1~3
Figure 4A~4E
Figure 5
AI summary
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).